| In silico models |
In silico toxicology protocols |
Regulatory Toxicology and Pharmacology, 96, 1-17, |
2018 |
[@349519] |
| In silico models |
Regulatory acceptance of in silico approaches for the safety assessment of cosmetic-related substance |
Computational Toxicology, 11, 82-89 |
2019 |
[@349474] |
| In silico models |
The role of validation in establishing the scientific credibility of predictive toxicology approaches intended for regulatory application |
Computational Toxicology, 17, 100144, |
2021 |
[@349552] |
| In silico models |
A review of in silico toxicology approaches to support the safety assessment of cosmetics-related materials. |
Computational Toxicology, 21, 100213, |
2022 |
[@349427] |
| (Q)SAR models |
Guidance document on the validation of (Quantitative) Structure-Activity relationships [(Q)SAR] models. Series on Testing and Assessment No 69 |
n.a. |
2007 |
[@349528] |
| (Q)SAR models |
(Q)SAR Assessment Framework: Guidance for the regulatory assessment of (Quantitative) Structure - Activity Relationship models, predictions, and results based on multiple predictions. OECD Series on Testing and Assessment, No. 386 |
n.a. |
2023 |
[@349544] |
| (Q)SAR models |
(Q)SAR tools for the prediction of mutagenic properties: Are they ready for application in pesticide regulation? |
Pest management science, 76(10), 3316–3325. |
2020 |
[@349483] |
| PBK models |
Guidance document on the characterisation, validation and reporting of Physiologically Based Kinetic (PBK) models for regulatory purposes, OECD Series on Testing and Assessment, No. 331 |
n.a. |
2021 |
[@349541] |
| PBK models |
Physiologically Based Pharmacokinetic Analyses — Format and Content Guidance for Industry. |
n.a. |
2018 |
[@349584] |
| PBK models |
Approaches for the Application of physiologically Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment (Final Report). |
n.a. |
2006 |
[@349581] |
| PBK models |
Characterization and application of physiologically based pharmacokinetic models in risk assessment |
n.a. |
2010 |
[@349593] |
| PBK models |
Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessmen |
Arch Toxicol, 96, 3407–3419 |
2022 |
[@349520] |
| PBK models |
Next generation physiologically based kinetic (NG-PBK) models in support of regulatory decision making. |
Computational Toxicology, 9, 61-72, |
2019 |
[@349548] |
| PBK models |
Gaining acceptance in next generation PBK modelling approaches for regulatory assessments–An OECD international effort. |
Computational Toxicology, 18, 100163, |
2021 |
[@349549] |
| PBK models |
PBPK Modeling of Slightly Soluble Silver Nanomaterials and Regulatory Acceptance |
Small , 16, 1907667 |
2020 |
[@349497] |